Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>This study aimed to explore the novel biomarkers for immune checkpoint inhibitor (ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and expression of programmed death receptor 1 ligand (PD‐L1).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and Methods</h3><p>Tumor and blood samples from 637 Chinese patients with NSCLC were collected for targeted panel sequencing. Genomic alterations, including single nucleotide variations, insertions/deletions, copy number variations, and gene rearrangements, were assessed and TMB was computed. TMB‐high (TMB‐H) was defined as ≥10 mutations/Mb. PD‐L1 positivity was defined as ≥1% tumor cells with membranous staining. Genomic data and ICI outcomes of 240 patients with NSCLC were derived from cBioPortal.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p><i>EGFR</i>‐sensitizing mutations, <i>ALK</i>, <i>RET</i>, and <i>ROS1</i> rearrangements were associated with lower TMB and PD‐L1+/TMB‐H proportions, whereas <i>KRAS</i>, <i>ALK</i>, <i>RET</i>, and <i>ROS1</i> substitutions/indels correlated with higher TMB and PD‐L1+/TMB‐H proportions than wild‐type genotypes. Histone‐lysine N‐methyltransferase 2 (<i>KMT2</i>) family members (<i>KMT2A</i>, <i>KMT2C</i>, and <i>KMT2D</i>) were frequently mutated in NSCLC tumors, and these mutations were associated with higher TMB and PD‐L1 expression, as well as higher PD‐L1+/TMB‐H proportions. Specifically, patients with KMT2C mutations had higher TMB and PD‐L1+/TMB‐H proportions than wild‐type patients. The median progression‐free survival (PFS) was 5.47 months (95% CI 2.5–NA) in patients with KMT2C mutations versus 3.17 months (95% CI 2.6–4.27) in wild‐type patients (<i>p</i> = 0.058). Furthermore, in patients with NSCLC who underwent ICI treatment, patients with TP53/KMT2C co‐mutations had significantly longer PFS and greater durable clinical benefit (HR: 0.48, 95% CI: 0.24–0.94, <i>p</i> = 0.033). TP53 mutation combined with KMT2C or KRAS mutation was a better biomarker with expanded population benefit from ICIs therapy and increased the predictive power (HR: 0.46, 95% CI: 0.26–0.81, <i>p</i> = 0.007). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>We found that tumors with different alterations in actionable target genes had variable expression of PD‐L1 and TMB in NSCLC. TP53/KMT2C co‐mutation might serve as a predictive biomarker for ICI responses in NSCLC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Implications for Practice</h3><p>Cancer immunotherapies, especially immune checkpoint inhibitors (ICIs), have revolutionized the treatment of non‐small cell lung cancer (NSCLC); however, only a proportion of patients derive durable responses to this treatment. Biomarkers with greater accuracy are highly needed. In total, 637 Chinese patients with NSCLC were analyzed using next‐generation sequencing and IHC to characterize the unique features of genomic alterations and TMB and PD‐L1 expression. Our study demonstrated that KMT2C/TP53 co‐mutation might be an accurate, cost‐effective, and reliable biomarker to predict responses to PD‐1 blockade therapy in NSCLC patients and that adding KRAS to the biomarker combination creates a more robust parameter to identify the best responders to ICI therapy.</p></section>

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

Identification of Nomogram Associated with Durable Clinical Benefit Gene for Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Immunotherapy

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Identification of Immune-Related Gene Signature for Non-Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors

A Mutation-Based Gene Set Predicts Survival Benefit after Immunotherapy Across Multiple Cancers and Reveals the Immune Response Landscape

Associations Between Interaction Effects of Mutational Events and Efficient Immunotherapy in Squamous NSCLC: Results from 373 Patients.

MA15.03 The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC

Therapeutic Guidance of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Comprehensive Meta-analysis

Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer

The Immune Response-Related Mutational Signatures and Driver Genes in Non-Small-cell Lung Cancer

Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)

Identification and Validation of a Genomic Mutation Signature As a Predictor for Immunotherapy in NSCLC.

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis

INTEGRATING TUMOR MUTATIONAL BURDEN AND TRANSCRIPTOME EXPRESSION INTO PREDICTION OF IMMUNE CHECKPOINT INHIBITOR RESPONSE AND PROGNOSIS OF PATIENTS WITH COLON CANCER

A New Immune Signature for Survival Prediction and Immune Checkpoint Molecules in Non-Small Cell Lung Cancer

Abstract 1614: the Effect of Tumor Mutation Burden on Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report

Relationship Between the Efficacy of Immunotherapy and Characteristics of Specific Tumor Mutation Genes in Non‐small Cell Lung Cancer Patients

A Predictive Model for Evaluating Efficacy of Immunotherapy in Non-small-cell Lung Cancer Patients